Disease control in young people with chronic conditions remains stable during transition to adult healthcare
9.4.2026 08:37:05 EEST | HUS | Press release
A recently completed study shows that the transition of young people with chronic conditions from pediatric specialized healthcare to services for adults goes well for most of them. Positive experiences of care and a carefully planned transfer process in particular support the stability of disease control. Mental wellbeing plays a more important role in the transition phase than previously known.

Researchers at HUS and the University of Helsinki investigated changes in disease control in young people with chronic conditions who were treated or monitored at the New Children's Hospital when transferring from pediatric healthcare to specialized healthcare for adults. In addition, it was examined how disease control and the young person’s mental disorder in addition to the primary disease were associated with the quality of life and experiences of care before and after the transfer.
A total of 253 young people participated in the study. Of them, 199 responded to the survey one year and 172 two years after the transfer. The average ages of the participants were 17, 18 and 20 years. Disease control could be determined for 99 per cent of the young people before the transfer and for more than 80 per cent one and two years after the transfer. Disease control was categorized as good, moderate or poor. The psychiatric diagnoses were obtained from medical records.
“In the majority of young people, disease control remained stable during the transition period,” says Specialist Mira Kallio from HUS Children and Adolescents.
A psychiatric illness was linked to worse disease control
The study found no significant differences in young people’s health-related quality of life or the overall score for experiences of care depending on whether their chronic condition was in good, moderate or poor control. However, in young people with a psychiatric illness, disease control and the health-related quality of life were lower both before and after the transfer. The study indeed highlights a more significant role of mental wellbeing in the transition phase than previously.
“Additional research is needed to find out how the differences that were observed in this study could be reduced better by supporting adolescents and young adults with chronic conditions who also have a psychiatric illness,” says Kallio.
In university hospitals research is part of treatment: new research outcomes make treatment practises more efficient and help focus treatments correctly. We work in close collaboration with the University of Helsinki and other universities, and we publish ca 3,000 peer-reviewed research articles annually.
Today’s research provides better care in the future.
Keywords
Contacts
Mira Kallio, tel. +358 50 427 8944, mira.kallio@hus.fi
HUS Children and Adolescents
Images

Links
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats 700,000 patients every year. Our 26,500 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
HUS-sammanslutningens styrelse sammanträder den 8 juni 20265.6.2026 15:15:48 EEST | Pressmeddelande
HUS-sammanslutningens styrelse sammanträder måndagen den 8 juni 2026 för att besluta om bland annat inledande av projektet för att förnya förvaltningens verksamhetsstyrningssystem, flera rörelseöverlåtelser samt valet av chefsöverläkare och kundrelationsdirektör. Föredragningslistan för mötet finns här. Sammanslutningens styrelse leder HUS verksamhet, förvaltning och ekonomi. Sammanslutningens styrelse har 17 ledamöter och av dem är två företrädare för Helsingfors universitet. Sammanslutningens styrelse sammanträder cirka en gång per månad. HUS medietjänst betjänar medier måndag–torsdag kl. 10–16, fredag kl. 10–15 på numret 050 427 2875 eller per e-post på viestinta@hus.fi. Se avvikande öppettider.
HUSin yhtymähallitus kokoontuu 8.6.20265.6.2026 15:15:48 EEST | Tiedote
HUSin yhtymähallitus kokoontuu maanantaina 8.6.2026 päättämään mm. toiminnannaohjausjärjestelmän uudistushankkeen käynnistämisestä, useammasta liikkeenluovutuksesta sekä HUS-yhtymän johtajaylilääkärin ja asiakkuusjohtajan virkavalinnoista. Kokouksen esityslistan pääset lukemaan täältä. Yhtymähallitus johtaa HUSin toimintaa, hallintoa ja taloutta. Yhtymähallituksessa on 17 jäsentä, joista kaksi on Helsingin yliopiston edustajia. Yhtymähallitus kokoontuu noin kerran kuukaudessa. HUSin mediapalvelu palvelee mediaa ma–to klo 10–16, pe klo 10–15 numerossa 050 427 2875 tai sähköpostitse viestinta@hus.fi. Katso poikkeusaukioloajat
I Finland inleds en ny nationell FINACCESS-studie – målet är att förbättra tillgången till nya cancerläkemedel för finländska patienter4.6.2026 08:15:00 EEST | Pressmeddelande
HUS koordinerar den nya nationella läkemedelsstudien FINACCESS, vars syfte är att förbättra patienternas tillgång till nya cancerläkemedel samt att ge värdefull information om behandlingarnas effekt och säkerhet.
Suomessa käynnistyy uusi kansallinen FINACCESS-tutkimus – tavoitteena parantaa uusien syöpälääkkeiden saatavuutta suomalaisille potilaille4.6.2026 08:15:00 EEST | Tiedote
HUS koordinoi uutta kansallista FINACCESS-lääketutkimusta, jonka tavoitteena on parantaa uusien syöpälääkkeiden saatavuutta potilaille sekä tuottaa arvokasta tietoa hoitojen vaikuttavuudesta ja turvallisuudesta.
A new national study launched in Finland: FINACCESS aims to improve access to new cancer medicines for Finnish patients4.6.2026 08:15:00 EEST | Press release
HUS is coordinating a new national cancer medicines study, FINACCESS, which aims to improve patients’ access to new cancer medicines while generating valuable data on the efficacy and safety of treatments.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom